Bilingual Therapies competitors

As chief executive officer of Magellan Rx Management, Mostafa Kamal is responsible for all of Magellan’s pharmacy business lines, including the commercial, government and specialty pharmacy divisions. He leads the strategy, operations, growth and profitability of Magellan Rx Management with the overarching goal of delivering innovative, best-in-class drug management solutions to help clients improve the health of the people they serve, as well as the overall quality and cost of care. Previously, Kamal was senior vice president and general manager of Magellan Rx Management’s specialty pharmacy business. In this role, he led sales, account management, operations and product development across the division, delivering industry-leading strategies and solutions to help clients successfully manage complex specialty pharmaceuticals in one of the fastest growing areas of healthcare spending. As chief underwriting officer, he directed the organization’s overall pricing and risk management strategies, and served as vice president of pricing, underwriting and analytics, where he developed financial strategies to help clients manage their pharmacy spend. Before joining Magellan, Kamal held various roles with Medco Health Solutions, Inc., with responsibility for pricing, underwriting, strategy and Medicare Part D products and services. Additionally, he worked with clients to develop strategies to address healthcare reform and associated product offerings to ensure clients were successfully positioned in the post-healthcare reform era. Kamal received his bachelor’s degree in economics from Rutgers University.

James L. Madara, MD, serves as the CEO and executive vice president of the American Medical Association, the nation’s largest physician organization. He holds the academic title of adjunct professor of pathology at Northwestern University. Since taking the reins of the AMA in 2011, Dr. Madara has helped sculpt the organization’s visionary long-term strategic plan. As an extension of this vision, he now also serves as chairman of Health2047 Inc., an independent, design-driven innovation firm based in San Francisco whose mission is to help advance the AMA’s goal of improving the health of the nation. Prior to arriving at the AMA, Dr. Madara spent the first 22 years of his career at Harvard Medical School, receiving both clinical and research training, serving as a tenured professor and as director of the NIH-sponsored Harvard Digestive Diseases Center. Following 5 years as chair of pathology at Emory, Dr. Madara served as dean of the medical school and CEO of the hospitals at the University of Chicago, bringing together the university’s biomedical research, teaching and clinical activities. While there, he oversaw the renewal of the institution’s biomedical campus and engineered significant new affiliations with community hospitals, teaching hospital systems, community clinics and national research organizations. Dr. Madara also served as senior advisor with Leavitt Partners, an innovative health care consulting and private-equity firm founded by former Secretary of Health and Human Services, Mike Leavitt. Having published more than 200 original papers and chapters, Dr. Madara has received both national and international awards, and served as editor-in-chief of the American Journal of Pathology and as president of the American Board of Pathology. In addition to Modern Healthcare consistently naming him as one of the nation’s 50 most influential physician executives, as well as one of the nation’s 100 most influential people in health care, he is a past recipient of a prestigious MERIT Award from the National Institutes of Health. He received the 2011 Davenport Award for lifetime achievement in gastrointestinal disease from the American Physiological Society and the 2011 Mentoring Award for lifetime achievement from the American Gastroenterological Society. Dr. Madara is an elected member of both the American Society of Clinical Investigation and the Association of American Physicians. He also co-chairs the Value Incentives and Systems Innovation Collaborative of the National Academy of Medicine (NAM), and is a member of NAM’s Leadership Consortium for Value & Science-Driven Health Care. Dr. Madara and his wife Vicki have 2 children, Max and Alexis.